Single-nucleus transcriptome atlas of orbitofrontal cortex in ALS with a deep learning-based decoding of alternative polyadenylation mechanisms https://t.co/aWHnaF0w2q
Excited to share my PhD work (with Dr Janice Robertson) just published in Acta Neuropathologica Communications! We developed TDP-43 mouse models, showing how C9orf72 loss worsens TDP-25 pathology via impaired autophagy. https://t.co/E8kE7xhryq
FUS implicated in cognitive & behavioral dysfunction in ALS, nominating FUS mislocalization & its downstream gene network as therapeutic targets. Delighted to contribute with @jennagregory488 - work driven by @SalimMegat, Raphaelle Cassel & Luc Dupuis.
https://t.co/MwjG3BWX9u
We’re happy to share that our labs first #ALS and #FTD study “A stress-dependent TDP-43 SUMOylation program preserves neuronal function” is now online @MolNeuro!
https://t.co/fqv8ivFde4
Ecstatic to see our paper "Long-read RNA sequencing atlas of human microglia isoforms elucidates disease-associated genetic regulation of splicing" now published in @NatureGenet with @towfiqueRaj@panos_roussos@SinaiBrain https://t.co/B0qIQJoIuA
My company Neuropeutics Inc has partnered with medical research charity @lifearc1 to develop a new drug for ALS.
Connect with us to join our mission!
Read more: https://t.co/0Rhez9aLmp
Today, ALS Canada celebrates a monumental advocacy achievement: the Ontario Government's commitment of $13 million over three years in the 2024 Fall Economic Statement to support the Ontario Provincial ALS Program.
To the ALS community, thank you. Together, we did this. This significant milestone was reached because of your collective action and tireless advocacy for change.
To read more about the Ontario Provincial ALS Program and the Ontario government’s investment, visit https://t.co/EviKTy5Leq.
📣 2025 ALS Canada Canadian ALS Learning Institute applications are now open! 📣
Tre Archibald, 2022 CALI graduate and ALS Canada Community Ambassador, shares his experience in the program. The application deadline is Mon., Nov. 18. To apply today, visit https://t.co/prZhmOMZne.
Delighted to share our latest paper 'Severe dynein dysfunction in cholinergic neurons exacerbates ALS-like phenotypes in a new mouse model'. Read at https://t.co/MpNL958zJA
Funded by MND Association @mndassoc
Tofersen is first global proven transformational treatment for small part of our #mnd#als community & in UK we are having issues with @NICEComms approving. It’s for about 100 people in UK. They matter!
Please help us & sign the petition.
#united2endmnd
Please sign the petition
Did you know that nuclear pore complexes can turn up outside the nuclear envelope? Studying these, @JennySachweh, Bernhard Hampoelz and others uncover that the surrounding cellular milieu determines NPC composition via the nuclear transport system itself. #teamtomo#NPC A 🧵
Congrats to @RitaSattler on her @AZALZConsortium grant, which will support her lab as they continue investigating the role of TDP-43 protein aggregates in neurodegenerative diseases including #Alzheimers—an important step toward development of new treatments #WorldAlzheimersMonth
NEMF mutations in mice illustrate how Importin-β specific nuclear transport defects recapitulate neurodegenerative disease hallmarks: https://t.co/yCkeKL37bQ
📚 👏 In partnership with the Kevin Daly Bursary Fund, we are proud to announce four recipients of the 2024 ALS Canada Kevin Daly Bursary – Emma Heaney, Tristan Hopkins, Alexandra McLaren, and Zachary Wood! To read our announcement, visit https://t.co/E9QjyM2jsr.
Last week, ALS Canada had the pleasure of visiting #ALS researcher @DrDDOM and his lab at @UWaterloo. Dr. Martin & his lab are a group of passionate researchers dedicated to advancing our understanding of the disease to develop more effective therapies for people affected by ALS.